Latest news and press releases about Celcuity Inc. (CELC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.
Price
| Price | $82.58 |
| Market Cap | $4.0B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -346.28 |
| EV / EBITDA | -24.86 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -350.78% |
| Return on Invested Capital | -28.14% |
| Return on Assets | -27.35% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AAPG · APGE · CGON · CNTA · IRON · LEGN · RARE
Explore sector: Healthcare · Biotechnology
More sections of CELC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks